Latest Conference

Unaddressed mental health challenges among youth living with HIV complicate antiretroviral therapy (ART) adherence, leading to high mortality and lower rates of viral suppression among this population.

Contagion® spoke to Onyema Ogbuagu, MD, who presented the week 96 results from the DISCOVER study evaluating F/TAF and F/TDF.

There was a statistically significant difference in renal safety which favored F/TAF over F/TDF at Week 96.

The rate of viral suppression among US youth aged 13 to 24 with HIV (YWH) hovers between 12 and 26%, representing an important clinical and public health challenge.

The time is now to put in place comprehensive action plans now to monitor, detect, and respond to treatment failure on dolutegravir.

The abstract authors report that both HIV viral load in plasma and proviral HIV DNA in CD4 cells have remained below levels of detection for up to 30 months.

Reducing barriers to care is paramount for people living with HIV and one such barrier in some countries, such as Zimbabwe, is high treatment loads that affect health system efficiency.

Women living with HIV who are on an antiretroviral therapy regimen of dolutegravir experienced persistently higher weight postpartum compared with women on efavirenz in Botswana.

“There are structural drivers that are impeding prevention and treatment among people who inject drugs,” Strathdee said in an interview with Contagion®.

For African men living with HIV who are not virally suppressed, community-based antiretroviral therapy (ART) significantly increased viral suppression compared with clinic-based ART.

New Week 96 data from the FLAIR study indicate that once-monthly injections of cabotegravir and rilpivirine remains non-inferior and safe when compared with the daily, oral 3-drug regimen of ABC/DTG/3TC.

A team of investigators hypothesized that prevalent syphilis infection in women with and without HIV may be a way to identify individuals who are at an elevated risk of a stillbirth over time.

Despite the high level of knowledge surrounding immediate initiation of ART, the practice is not yet the standard of care across clinics in NYC.

An international team of investigators shares 48-week results from ATLAS-2M, which tested out every other month dosing of the intramuscular injection compared with monthly dosing.

Investigators conducted 2 studies on intravenously administered GS-9722, 1 in HIV-negative participants and 1 in virally suppressed people with HIV.

A generic pre-exposure prophylaxis (PrEP) option would greatly expand coverage among vulnerable populations and may well be the most cost-effective and safe option.

Patients who had OUD and sepsis were found to be younger and healthier than patients without OUD.

To evaluate the algorithm, the investigators looked at hospital encounters to determine trends in incidence and mortality from January 2011 through January 2019.

Andrea L. Cox, MD, PhD, comments on the future of HCV vaccine development efforts in light of the 2019 trial which did not prevent chronic infection.

Andrea L. Cox, MD, PhD, discusses the implications of discovering that an experimental vaccine was not effective at preventing chronic hepatitis C virus.

Daniel B. Chastain, PharmD, BCIDP, AAHIVP, clinical assistant professor at the University of Georgia College of Pharmacy, explains antiretroviral stewardship.

Pamela Gorman, RN, ACRN, describes the benefits of connecting care to incarcerated people with HIV.

Pamela Gorman, RN, ACRN, describes a transitional care coordination program for incarcerated individuals with HIV returning to the community primary care setting.

Rasheeta Chandler, PhD, RN, APRN-BC, FNP-BC, FAANP, FAAN, explains the need to incorporate women at-risk for or living with HIV into the decision-making process if we are to end the epidemic.

Max Brito, MD, MPH, remarks on the underrepresentation of transgender women in HIV and other sexual health research.

A team of pharmacists at Baptist Hospital reported that improving penicillin allergy documentation and increasing the use of β-lactams had potential cost savings of $21,468 over a 3-month period.

Representatives from the AIDS Care Group discuss the racial disparities that exist in the HIV/AIDS care continuum for women of color, as well as how a peer engagement and retention program can help.

Timothy Ray Brown, also known as the "Berlin Patient" discusses why it's important to push out the message that U=U.

Pamela Gorman, RN, ACRN, discusses how electronic health data and coordinated outreach can be combined to increase retention in care.

In 2010, Timothy Ray Brown came forward as the "Berlin Patient" and has become an advocate for people living with HIV. He hopes to see the day when all individuals when HIV can be cured safely.